PDF(Pubmed)
Abstract：
Bedaquiline is currently a key drug for treating multidrug-resistant or rifampin-resistant tuberculosis. We report and discuss the unusual development of resistance to bedaquiline in a teenager in Namibia, despite an optimal background regimen and adherence. The report highlights the risk for bedaquiline resistance development and the need for rapid drug-resistance testing.
摘要：
Bedaquiline目前是治疗耐多药或利福平耐药结核病的关键药物。我们报告并讨论了纳米比亚一名青少年对bedaquiline的耐药性的异常发展，尽管有最佳的背景方案和依从性。该报告强调了bedaquiline耐药性发展的风险以及快速耐药性测试的必要性。
